Scott Daigle
About Scott Daigle
Scott Daigle serves as the Senior Director of Translational Medicine at Nimbus Therapeutics, a position he has held since 2023. He has extensive experience in the pharmaceutical industry, having previously worked at Merck, Servier Pharmaceuticals, Agios Pharmaceuticals, and Bayer HealthCare.
Work at Nimbus
Scott Daigle has been serving as the Senior Director of Translational Medicine at Nimbus Therapeutics since 2023. In this role, he focuses on bridging the gap between preclinical research and clinical development, ensuring that innovative therapies are effectively translated into clinical applications. His expertise in translational medicine contributes to the advancement of Nimbus Therapeutics' mission to develop transformative medicines.
Current Role at Servier Pharmaceuticals
In addition to his position at Nimbus Therapeutics, Scott Daigle has held the role of Director of Translational Medicine at Servier Pharmaceuticals since 2021. His responsibilities include overseeing translational strategies that facilitate the progression of drug candidates through the development pipeline. His experience in this capacity enhances Servier's commitment to delivering effective therapeutic solutions.
Previous Experience at Agios Pharmaceuticals
Prior to his current roles, Scott Daigle worked as Director of Translational Medicine at Agios Pharmaceuticals from 2018 to 2021. During his tenure, he contributed to the development of targeted therapies in oncology and rare genetic diseases. His work at Agios Pharmaceuticals involved collaborating with cross-functional teams to advance clinical programs.
Background in Research and Development
Scott Daigle's career in the pharmaceutical industry began at Bayer HealthCare, where he served as Senior Associate Scientist from 2000 to 2007. He then transitioned to Merck as a Research Biologist from 2007 to 2009. His extensive background in research and development has provided him with a strong foundation in the scientific principles underlying drug development.
Education and Expertise
Scott Daigle holds a Master of Science in Cell and Molecular Biology from the University of New Haven, where he studied from 1999 to 2001. He also earned a Bachelor of Science in Biology from Plymouth State University, completing his studies from 1995 to 1999. His educational background equips him with the knowledge necessary for his roles in translational medicine.